Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 4

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 4
---
 operating activities 
     (1,063,041) 
     (65,165)

    Cash Flows from Financing Activities: 

    Proceeds from note payable, related parties 
     -  
     45,000 
  
    Net cash flows from financing activities 
     -  
     45,000 

    Net Change in Cash 
     (1,063,041) 
     (20,165)

    Beginning of period 
     3,769,510  
     28,478 
  
    End of period 
    $2,706,469  
    $8,313 

    Supplemental disclosure of cash flow information: 

    Cash paid for interest 
    $146  
    $28,128 
  
    Cash paid for income taxes 
    $-  
    $- 

    Non-Cash Investing and Financing Activities: 

    Restricted stock issued for the forgiveness of accrued compensation 
    $-  
    $10,000 
  
    Stock options issued for the forgiveness of accrued compensation 
    $-  
    $50,000 

The accompanying notes are an integral part of these
condensed consolidated financial statements

8

JUPITER NEUROSCIENCES, INC.

NOTES TO CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2025

Note 1 – Organization and Description
of Business

Jupiter Neurosciences, Inc. (the “Company”)
is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware
in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation.
The product candidate, called JOTROL, has many potential indications of use for rare diseases. We are primarily targeting Mucopolysaccharidoses
Type 1, Friedreich’s Ataxia, and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild
Cognitive Impairment/early Alzheimer’s disease.

JOTROL has the potential to deliver a therapeutically
effective dose of resveratrol in the blood stream, using a unique patented micellar formulation, without causing gastrointestinal side
effects. We expect JOTROL, based on the results of our Phase I study, will resolve the major obstacle of resveratrol’s poor bio